Efficacy of Micro-excisional Skin Removal by Micro-coring Device in Treatment of Wrinkles and Laxity of Face and Neck

Laxity; Skin Clinical Trial

— MCD  

Official title:

A Prospective, Multi-center, Pilot Study to Evaluate the Efficacy of Micro-Excisional Skin Remodeling With Micro-Coring Device in the Treatment of Wrinkles and Skin Laxity of Face and Neck

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03583918
• Other study ID #: Optimization of MCD treatment
• Secondary ID: AIS 700-00022
• Status: Completed
• Phase: N/A
• Start date: June 1, 2017
• Est. completion date: June 13, 2018

Study information

• Verified date: July 2018
• Source: Cytrellis Biosystems, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, multi-center, pilot study evaluating effectiveness of micro-excisional skin remodeling by micro-coring skin in subjects meeting the Inclusion Criteria. Subjects will undergo bilateral treatment on the face and neck (upper and lower cheek, upper and lower lip, periocular and perioral areas, submandibular and middle neck, etc). The exact treatment area(s), choice of treatment density are left to the Investigator's discretion and subject's consent. Up to 3 treatments are allowed with a minimum of 30-day between the consecutive treatments.

Description:

The study will enroll up to 50 subjects at 6-8 investigational sites. It will evaluating effectiveness of a micro-coring device for micro-excisional skin remodeling in subjects with moderate to severe wrinkles of face and neck who meet the Inclusion/Exclusion Criteria. The choice of treatment density is at the investigator's discretion with the subject's consent. Up to 3 treatments may be performed with a minimum of 30-day interval between the consecutive treatments. Subjects will undergo bilateral micro-coring of skin on the face and upper neck, including but not limited to upper and lower cheek, upper and lower lip, periocular and perioral areas, submandibular and upper neck. The exact area(s) of treatment are left to the Investigator's discretion and subject's consent.

The subjects will be evaluated at each visit and following data will be collected:

• The incidence and severity of systemic and local adverse events.

• Wrinkle severity score assessed using the Lemperle Wrinkle Severity Scale.

• Changes in skin laxity assessed by Laxity Scale.

• Canfield Image Analyses.

• Needle and/or punch biopsy (in some subjects).

• Overall aesthetic improvement using the following scales:

• Subject and PI Global Aesthetic Improvement Scale (GAIS)

• Subject Satisfaction Scale

• Rhytides and Laxity Scale

• Lower face assessment

• Investigator evaluation of device usability and functionality. Data Analysis: Analyses will be conducted per measurement tools listed. Statistical analysis will include but will not be limited to T tests, univariate and multivariate analysis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: June 13, 2018
• Est. primary completion date: June 13, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Fitzpatrick Skin Type 1, 2, or 3 as judged by the Investigator

• Two or more of the following: Facial wrinkles assessed using the Lemperle Wrinkle Assessment Scale (descriptive and pictorial)

• Cheek fold lines >2

• Upper lip lines >3

• Nasolabial Folds >3

• Marionette lines >3

• Labiomental crease >3

• Corner of the mouth lines >3

• Periocular lines >3

• Able to provide written informed consent, understand and willing to comply with all study related directions from investigator and follow-up visits.

Exclusion Criteria:

• Lesions suspicious for any malignancy or the presence of actinic keratosis, melasma, vitiligo, cutaneous papules/nodules or active inflammatory lesions in the areas to be treated

• History of keloid formation or hypertrophic scarring

• History of trauma or surgery to the treatment areas in the past 6 months

• Scar present in the areas to be treated

• Silicone or synthetic material injections in the areas to be treated

• Injection of FDA-approved dermal fillers in the past two years

• Injection of fat in the past year

• History of treatment with dermabrasion, ablative laser, or radiofrequency in the past year

• History of treatment with non-ablative laser in the past 6 months

• History of treatment with botulinum toxin injections in the areas to be treated within the prior 6 months

• Active smokers (0.5 pack/day) or having quit within 3 months prior to treatment

• Active, chronic, or recurrent infection

• History of compromised immune system or currently being treated with immunosuppressive agents

• History of sensitivity to analgesic agents, Aquaphor®, topical or local anesthetics (e.g., lidocaine, benzocaine, procaine) or chlorhexidine, povidone-iodine or epinephrine

• Excessive sun exposure and use of tanning beds or tanning creams within 30 days prior to treatment

• Treatment with aspirin or other blood thinning agents within 14 days prior to treatment

• History or presence of any clinically significant bleeding disorder

• Co-morbid condition that in the Investigator's opinion could limit ability to participate in the study or to comply with follow-up requirements

• History of drug and/or alcohol abuse

• Any issue that, at the discretion of the Investigator, would interfere with assessment of safety or efficacy or compromise the subject's ability to undergo study procedures or give informed consent

• Treatment with an investigational device or agent within 30 days before treatment or during the study period

Related Conditions & MeSH terms

• Cutis Laxa
• Laxity; Skin

Intervention

Device:
• HighThroughput Micro Coring Device
Assess Safety and Efficacy for skin treatments through micro-excisional skin removal with micro-coring device

Locations

Country	Name	City	State
United States	Dr A Jay Burns Cosmetic Surgery	Dallas	Texas
United States	Miami Dermatology and Laser Institute	Miami	Florida
United States	The Practice of Brian S. Biesman, M.D	Nashville	Tennessee
United States	Laser and Skin Surgery Center of New York	New York	New York
United States	Laser and Skin Surgery Center of Northern California	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Cytrellis Biosystems, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess wrinkle reduction for moderate to severe wrinkles at 90 days post treatment based on the Lemperle Wrinkle Scale	Assess wrinkle reduction in wrinkle severity score from the baseline assessed by Independent Reviewer(s) using the Lemperle Wrinkle Severity Scale. No wrinkles = 0; Just perceptible wrinkles = 1; Shallow wrinkles = 2; Moderately deep wrinkles = 3; Deep wrinkles, well-defined edges = 4; Very deep wrinkles, redundant fold = 5	90-day post-treatment
Secondary	Assess skin laxity Improvement at 90 days post treatment	Improvement in skin laxity score from the baseline assessed by Independent Reviewer using Laxity Scale and supplemented by the Canfield Image Analyses. Global Aesthetic Improvement Scale: 3 Very Much Improved; 2 Much Improved; 1 Improved; 0 No Change; - 1 Worse; - 2 Much Worse; -3 Very Much Worse.	90-day post-treatment
Secondary	Assess skin for new collagenases	Histological changes in treated skin when compared to untreated skin consistent with new collagenases	60, 90, 180-day post treatment